 |
|
|
|
|
|
 |
 |
 |
 |
 |
|
Elusys Therapeutics is committed to developing new biotherapeutic products that dramatically improve treatment of life-threatening infectious disease.
|
ANTHIM®
|
|
|
|
ETI-211
|
|
|
|
Heteropolymer Antibodies
|
NEWS
July 15th, 2010
Elusys Therapeutics and Lonza extend manufacturing agreement for Anthim...
read more >>
January 4th, 2010
Elusys receives contract for up to $143 million from the U.S. Government...
read more >>
Elizabeth Posillico, PhD inducted into NJ’s High Tech Hall of Fame
read more >>
LEARN MORE ABOUT...
Our product pipeline
New approaches for the treatment of infectious disease
learn more >>
Working at Elusys
A dynamic, creative environment to advance your career
learn more >>